Breaking News, Financial News

Financial Reports: Biogen Idec

MS franchise continues growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 1Q13 1Q Revenues: $1.4 billion (+10%) 1Q Earnings: $427 million (+41%) Comments: Avonex sales rose 13% ($746 million), Tysabri rose 9% ($312 million), Fampyra was up 54% ($23 million) and Fumaderm was up 8% ($14 million). Rituxan revenues from its joint business arrangement fell 7% to $265 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters